Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    member health
    Human Health
    member startups
    Startups
    member non R&D
    Non-R&D Companies
    Member Savings
    BBS-Programs-vwr
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Asia-Taiwan
    BIO Europe

    November 3-5, 2025
    Vienna, Austria

    BIO Investor Forum
    Partnering @JPM Week

    January 12-15, 2026
    San Francisco, CA

    BIO Patient & Health Advocacy Summit
    BIO Investment & Growth Summit

    March 2-3, 2026
    Miami, FL

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
    Diversity & Inclusion >

    Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry.

  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipDiversity & InclusionBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3103 results found
Expand All
Apply All
3103 results found

BIO Statement Ahead of Chinese Vice Premier Visit to Washington
Share
Food & Farm Innovation  •  Press Release  •  January 29, 2019
"President Trump has taken unprecedented measures to take on China – our largest trading partner – for its history of trade abuses. Beijing has long imposed unjustified restrictions on U.S. companies seeking to do business in and export to China, particularly with respect to agricultural products. "With Chinese Vice Premier Liu He in Washington to participate in bilateral trade talks, the Trump administration should remain steadfast in pushing China towards structural reforms of its market. This means that any prospective trade deal with China cannot be based simply on a promise to buy more U.S. products. Such a bargain would fail to address the longstanding impediments that have contributed to the trade deficit with China. "Any trade deal must require systemic change from China when it comes to U.S. agricultural exports. It’s time for the Chinese government to implement a predictable, timely, transparent and science-based decision-making process that facilitates trade and the importation of agricultural biotechnology products. "Under China’s current opaque regulatory system for agriculture, Beijing arbitrarily dictates what technologies our farmers can use to address production challenges such as pests and drought. This month, Beijing approved only five of the 10 biotechnology crops seeking Chinese market access. Many of the still-unapproved products have languished in China’s regulatory process for more than six years – with no rational or legitimate scientific basis for the hold-up.  "As we near the March 1 deadline for a trade deal, U.S. Trade Representative Robert Lighthizer, Treasury Secretary Steve Mnuchin and Commerce Secretary Wilbur Ross must be resolute and insist on a deal with enduring commitments and not only purchases of U.S. goods. Any trade deal lacking fundamental reform is inadequate and only will exacerbate the inequities in our existing trading relationship that President Trump rightly is trying to…
Read More

BIO's Comment on Advanced Notice of Proposed Rulemaking Regarding Review of Controls for Certain Emerging Technologies
Share
Intellectual Property  •  Letters, Testimony & Comments  •  January 17, 2019
BIO urges the Administration to fully assess the potential impact of export controls on biotechnologies on “the impact on the economy of the United States” and on the sustainability of the U.S.’s global leadership in biotechnology, and pursue them “only to the extent necessary” to ensure national security, in accordance with the ECRA statement of policy for export controls in section 4811(1). Before proposing export controls on specific biotechnologies, the Commerce Department should assess the impact of each potential export control on the health of the biotechnology and life sciences ecosystem by evaluating the impact on domestic research, investment into U.S. companies developing or utilizing those technologies, and their ability to recruit and retain skilled talent necessary to develop or deploy those technologies.  
Read More

BIO Statement on China Approvals of Agricultural Biotechnology Products
Share
Food & Farm Innovation  •  Press Release  •  January 17, 2019
Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement on the announcement that the People’s Republic of China’s National Biosafety Committee approved the final safety certificate for five agricultural biotechnology products.
Read More

New Platform for Innovation in Food and Agriculture Launches, Invites Broad Conversation
Share
Food & Farm Innovation  •  Press Release  •  January 16, 2019
WASHINGTON, DC – Jan. 16, 2019 – Today, the Biotechnology Innovation Organization (BIO) and the American Seed Trade Association (ASTA) jointly announce the launch of Innovature, a new platform to spark a thoughtful dialogue around innovation in food and agriculture, with an initial focus on gene editing. Growing understanding of gene editing is spurring new developments in food and agriculture to address some of our most pressing societal challenges.
Read More

BIO Submits Comments on Priorities for United States - United Kingdom Trade Agreement
Share
Agriculture & Environment  •  Letters, Testimony & Comments  •  January 15, 2019
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to respond to the U.S. Trade Representative’s (USTR) request for comments on negotiating objectives for a United States (US) – United Kingdom (UK) Trade Agreement.
Read More

BIO's Comments on the Expanded CFIUS Review Pilot Program
Share
Human Health  •  Letters, Testimony & Comments  •  January 15, 2019
Comment letter to Treasury on the CFIUS pilot program 
Read More

BIO Applauds House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act
Share
Biodefense, Vaccines  •  Press Release  •  January 11, 2019
“Members of the House have sent a strong signal to the American people about their commitment to prioritizing health security by providing the resources needed to fully prepare for and defend against biological threats. Strengthening the pipeline of medical products, drugs and devices that will safeguard the nation during an emergency or pandemic is vital to our national security."
Read More

Advance Notice of Proposed Rulemaking: International Pricing Index Model for Medicare Part B Drugs
Share
Cost & Value of Biopharmaceuticals  •  Letters, Testimony & Comments  •  December 31, 2018
BIO strongly opposes the potential proposal detailed in the Advance Notice of Proposed Rulemaking (ANPRM) on the International Pricing Index (IPI) and calls for withdrawal of the IPI model in its entirety.
Read More

BIO Files Amicus Brief on Case Addressing the America Invents Act’s Joinder Provision
Share
Amicus Brief  •  December 28, 2018
BIO files an Amicus Brief on rehearing by the Precedential Opinion Panel of the Patent Trial and Appeal Board.
Read More

BIO Applauds House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act
Share
Biodefense  •  Press Release  •  December 21, 2018
Washington, DC (December 20, 2018) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement applauding passage today by the House of Representatives of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (H.R. 7328). The legislation would re-authorize critical federal biodefense programs and agencies, including the BioShield Special Reserve Fund (SRF), the Biomedical Advanced Research and Development Authority (BARDA), and the Strategic National Stockpile (SNS).
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 255
  • 256
  • 257
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO International Convention
BIO Partnering at JPM Week
BIO CEO & Investor Conference
BIO Investor Forum
BIO Patient Health & Advocacy Summit
BIO Intellectual Property Counsels Committee Conference
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2025 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO